Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) started the day on Wednesday, with a price increase of 6.27% at $1.78, before settling in for the price of $1.67 at the close. Taking a more long-term approach, GLMD posted a 52-week range of $1.15-$23.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its Annual Earning per share during the time was 45.91%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 64.49%. This publicly-traded company’s shares outstanding now amounts to $2.26 million, simultaneously with a float of $2.19 million. The organization now has a market capitalization sitting at $4.02 million. At the time of writing, stock’s 50-day Moving Average stood at $1.4294, while the 200-day Moving Average is $2.8317.
Galmed Pharmaceuticals Ltd (GLMD) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Galmed Pharmaceuticals Ltd’s current insider ownership accounts for 2.90%, in contrast to 9.88% institutional ownership.
Galmed Pharmaceuticals Ltd (GLMD) Earnings and Revenue Records
Galmed Pharmaceuticals Ltd’s EPS increase for this current 12-month fiscal period is 64.49% and is forecasted to reach -0.85 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 62.35% through the next 5 years, which can be compared against the 45.91% growth it accomplished over the previous five years trading on the market.
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Trading Performance Indicators
Let’s observe the current performance indicators for Galmed Pharmaceuticals Ltd (GLMD). It’s Quick Ratio in the last reported quarter now stands at 9.02. The Stock has managed to achieve an average true range (ATR) of 0.12.
In the same vein, GLMD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -6.99, a figure that is expected to reach -0.83 in the next quarter, and analysts are predicting that it will be -0.85 at the market close of one year from today.
Technical Analysis of Galmed Pharmaceuticals Ltd (GLMD)
If we take a close look at the recent performances of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD), its last 5-days Average volume was 0.48 million that shows plunge from its year to date volume of 1.37 million. During the previous 9 days, stock’s Stochastic %D was recorded 77.31% While, its Average True Range was 0.1137.
Raw Stochastic average of Galmed Pharmaceuticals Ltd (GLMD) in the period of the previous 100 days is set at 26.81%, which indicates a major fall in contrast to 88.89% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 57.15% that was lower than 108.87% volatility it exhibited in the past 100-days period.
